Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aprea Therapeutics, Inc.APRE · Entity 7948 | Director · President/CEO | March 12, 2026 | March 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aprea Therapeutics, Inc.
Report date March 12, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 393,895 |
Reported balance
After 2026-03-12 transaction · row 1
1 source rowRow 1 · 2026-03-12 · Grant · Acquired 20,175 · Balance 393,895 F1: These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2036-03-12 | Direct | 80,700 |
Reported balance
After 2026-03-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-12 · Grant · Acquired 80,700 · Balance 80,700 F3: Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |
| Common StockSEC Table I · non-derivative | IndirectBy Daughter | 1,200 |
Reported balance
Holding disclosure · report date 2026-03-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,200 F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Son | 600 |
Reported balance
Holding disclosure · report date 2026-03-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 600 F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3: Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2026 Filed Mar 16, 2026 18:07 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 80,700 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001104659-26-028656 · tm268953-2_4seq1.xml · derivative · entry 4 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,700 Underlying: Common Stock · 80,700 shares Expires 2036-03-12 F3 · derivative.exercise_date: Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 18:07 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 20,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-028656 · tm268953-2_4seq1.xml · nonDerivative · entry 1 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,895 F1 · shares: These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 16:08 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Warrant · Derivative | 28,100 | Not disclosed Strike: $0.77 | Not disclosed |
DisclosureSEC source: 0001104659-26-009206 · tm264801-2_4seq1.xml · derivative · entry 4 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,100 Underlying: Common Stock · 28,100 shares Expires not disclosed F3 · price: The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise. F4 · price: The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144. F3 · derivative.expiration_date: The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise. F4 · derivative.expiration_date: The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 16:08 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 28,100 | $0.89 | $25,009.00 |
DisclosureSEC source: 0001104659-26-009206 · tm264801-2_4seq1.xml · nonDerivative · entry 1 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,720 F2 · shares: On January 28, 2026, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on January 30, 2026, an aggregate of 28,100 shares of the Issuer's common stock (the "Shares") at a purchase price of $0.89 per Share. The Reporting Person also received accompanying common warrants (the "Common Warrants") to purchase up to an aggregate of 28,100 Shares. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 08:30 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Warrants · Derivative | 21,459 | Not disclosed Strike: $1.04 | Not disclosed |
DisclosureSEC source: 0001104659-25-120152 · tm2533219-1_4seq1.xml · derivative · entry 5 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,459 Underlying: Common Stock · 21,459 shares Expires not disclosed F2 · security: On December 8, 2025, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on December 10, 2025 pre-funded warrants ("Pre-Funded Warrants") to purchase an aggregate of 21,459 shares of the Issuer's common stock ("Shares") at a purchase price of $1.165 per Pre-Funded Warrant. The Reporting Person also received accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 21,459 Shares. F4 · price: The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144. F4 · derivative.expiration_date: The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 08:30 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchasePre-Funded Warrant · Derivative | 21,459 | $1.17 Strike: $0.00 | $24,999.74 |
DisclosureSEC source: 0001104659-25-120152 · tm2533219-1_4seq1.xml · derivative · entry 4 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,459 Underlying: Common Stock · 21,459 shares Expires not disclosed F2 · security: On December 8, 2025, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on December 10, 2025 pre-funded warrants ("Pre-Funded Warrants") to purchase an aggregate of 21,459 shares of the Issuer's common stock ("Shares") at a purchase price of $1.165 per Pre-Funded Warrant. The Reporting Person also received accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 21,459 Shares. F3 · derivative.expiration_date: The Pre-Funded Warrants are immediately exercisable at any time after the date of issuance. Pursuant to the terms of the Pre-Funded Warrants, the Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Limitation") Read SEC document |
| April 03, 2025 Filed Apr 4, 2025 07:30 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 2,497 | $1.80 | $4,494.60 |
DisclosureSEC source: 0001104659-25-031991 · tm2511518-1_4seq1.xml · nonDerivative · entry 2 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,620 Read SEC document |
| April 03, 2025 Filed Apr 4, 2025 07:30 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 3,003 | $1.87 | $5,615.61 |
DisclosureSEC source: 0001104659-25-031991 · tm2511518-1_4seq1.xml · nonDerivative · entry 1 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,123 Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 16:30 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 26,900 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001104659-25-029914 · tm2510809-1_4seq1.xml · derivative · entry 4 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,900 Underlying: Common Stock · 26,900 shares Expires 2035-03-28 F3 · derivative.exercise_date: Twenty-five percent of these options vest on March 27, 2026, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 16:30 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 6,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-029914 · tm2510809-1_4seq1.xml · nonDerivative · entry 1 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,120 F1 · shares: These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 27, 2026, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| October 23, 2024 Filed Oct 24, 2024 08:30 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 500 | $3.92 | $1,957.50 |
DisclosureSEC source: 0001104659-24-111031 · tm2426748-1_4seq1.xml · nonDerivative · entry 1 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,395 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.91 to $3.92, inclusive. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 08:31 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 250 | $2.90 | $725.00 |
DisclosureSEC source: 0001104659-24-108964 · tm2426059-6_4seq1.xml · nonDerivative · entry 1 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,895 Read SEC document |
| October 14, 2024 Filed Oct 15, 2024 08:31 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 1,000 | $2.59 | $2,590.00 |
DisclosureSEC source: 0001104659-24-108375 · tm2426059-3_4seq1.xml · nonDerivative · entry 2 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,645 Read SEC document |
| October 10, 2024 Filed Oct 15, 2024 08:31 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 150 | $2.54 | $381.00 |
DisclosureSEC source: 0001104659-24-108375 · tm2426059-3_4seq1.xml · nonDerivative · entry 1 Gilad Oren · CIK 0001929300 · Director · President/CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,645 Read SEC document |
| March 28, 2024 Filed Mar 28, 2024 17:57 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 26,900 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-24-040642 · tm2410009-1_4seq1.xml · derivative · entry 4 Gilad Oren · CIK 0001929300 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,900 Underlying: Common Stock · 26,900 shares Expires 2024-03-28 F3 · derivative.exercise_date: Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 28, 2024 Filed Mar 28, 2024 17:57 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 6,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-040642 · tm2410009-1_4seq1.xml · nonDerivative · entry 1 Gilad Oren · CIK 0001929300 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,495 F1 · shares: These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 13, 2024 Filed Mar 14, 2024 20:51 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseTranche B Warrant · Derivative | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-034670 · tm248935-1_4seq1.xml · derivative · entry 3 Gilad Oren · CIK 0001929300 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires not disclosed F4 · derivative.exercise_price: The exercise price of the Tranche B Warrants is as follows: 1,000 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share. F6 · price: The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above. F5 · derivative.expiration_date: Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred. Read SEC document |
| March 13, 2024 Filed Mar 14, 2024 20:51 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseTranche A Warrant · Derivative | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-034670 · tm248935-1_4seq1.xml · derivative · entry 2 Gilad Oren · CIK 0001929300 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires not disclosed F1 · derivative.exercise_price: The exercise price of the Tranche A Warrants is as follows: 1,000 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share. F3 · price: The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above. F2 · derivative.expiration_date: Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred. Read SEC document |
| March 13, 2024 Filed Mar 14, 2024 20:51 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 2,000 | $7.29 | $14,580.00 |
DisclosureSEC source: 0001104659-24-034670 · tm248935-1_4seq1.xml · nonDerivative · entry 1 Gilad Oren · CIK 0001929300 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,770 Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 18:30 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001104659-23-031882 · tm239268d1_4.xml · derivative · entry 4 Gilad Oren · CIK 0001929300 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-03-09 F3 · derivative.exercise_date: Twenty-five percent of these options vest on March 9, 2024, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 18:30 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-031882 · tm239268d1_4.xml · nonDerivative · entry 2 Gilad Oren · CIK 0001929300 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,770 F1 · shares: These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 9, 2024 until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. F4 · balance_after: Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023. Read SEC document |
| August 23, 2022 Filed Mar 13, 2023 18:30 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | ConversionSeries A Non-Voting Convertible Preferred Stock · Derivative | 604,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-031882 · tm239268d1_4.xml · derivative · entry 3 Gilad Oren · CIK 0001929300 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,045,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of Common Stock any time at the option of the holder thereof, subject to certain limitations. On August 23, 2022, the Reporting Person converted 604,510 shares of Series A Non-Voting Convertible Preferred Stock into 6,045,100 shares of Common Stock. F2 · derivative.exercise_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of Common Stock any time at the option of the holder thereof, subject to certain limitations. On August 23, 2022, the Reporting Person converted 604,510 shares of Series A Non-Voting Convertible Preferred Stock into 6,045,100 shares of Common Stock. F2 · derivative.expiration_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of Common Stock any time at the option of the holder thereof, subject to certain limitations. On August 23, 2022, the Reporting Person converted 604,510 shares of Series A Non-Voting Convertible Preferred Stock into 6,045,100 shares of Common Stock. Read SEC document |
| August 23, 2022 Filed Mar 13, 2023 18:30 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | ConversionCommon Stock | 6,045,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-031882 · tm239268d1_4.xml · nonDerivative · entry 1 Gilad Oren · CIK 0001929300 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,375,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of Common Stock any time at the option of the holder thereof, subject to certain limitations. On August 23, 2022, the Reporting Person converted 604,510 shares of Series A Non-Voting Convertible Preferred Stock into 6,045,100 shares of Common Stock. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 17:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 148,700 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001104659-22-084763 · tm2222147-3_4seq1.xml · derivative · entry 2 Gilad Oren · CIK 0001929300 · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,700 Underlying: Common Stock · 148,700 shares Expires 2032-07-28 F2 · derivative.exercise_date: Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 17:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 101,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-084763 · tm2222147-3_4seq1.xml · nonDerivative · entry 1 Gilad Oren · CIK 0001929300 · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,314 F1 · shares: These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 33,766 shares on July 28, 2023, (ii) 33,767 shares on July 28, 2024 and (iii) 33,767 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.